GLP-1 / Metabolic injectable

Survodutide

By Hack SmithLast updated: How we research

Dual-action weight loss hormone activator

Common Uses
  • Weight Loss/Fat Loss (dual GLP/Glucagon agonist)
Evidence Grade
A — Strong — Human clinical trial data
Human randomized controlled trial data available.
Safety Notes

Thyroid C-cell tumor warning: Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome (based on rodent studies; human relevance uncertain) Monitor for signs of pancreatitis; discontinue if suspected Significant weight loss may include lean muscle mass — resistance training and adequate protein intake strongly recommended High rates of gastrointestinal adverse events; dose titration is essential for tolerability Use caution in patients with gastroparesis or severe GI motility disorders

Mechanism of Action

Survodutide is a dual agonist that activates both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). By stimulating GLP-1R, it enhances glucose-dependent insulin secretion, reduces appetite, and slows gastric emptying. Simultaneous glucagon receptor activation increases energy expenditure and promotes hepatic lipid oxidation, providing additive metabolic benefits beyond GLP-1 agonism alone. Key Pathways: GLP-1 receptor signaling (appetite suppression, incretin effect, delayed gastric emptying), Glucagon receptor signaling (increased hepatic glucose output acutely, enhanced energy expenditure and lipolysis), Hepatic lipid metabolism (reduced liver fat through glucagon-mediated fatty acid oxidation) The dual mechanism translates to substantial weight loss (dose-dependent, with effects comparable to or exceeding semaglutide) and significant HbA1c reductions in patients with type 2 diabetes. Additionally, the glucagon receptor component appears to drive reductions in liver fat content, with phase 2 trials showing meaningful improvements in metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis markers.

Common Dose Reference Ranges

Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.

Low
0.6
mg
Standard
2
mg
High
6
mg
🔬 Related compounds
RetatrutideMazdutideOrforglipronSemaglutideTirzepatide
🔒 Skool Members Only

Full Survodutide protocols — frequency, timing, cycle length, reconstitution & research

Frequency: Once weekly
Half-life: approximately 7 days (sufficient for once-weekly dosing)
Cycle length: 16 weeks
Side Effects
  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Decreased appetite
  • Gastroparesis risk / delayed gastric emptying
  • Pancreatitis
  • Thyroid C-cell tumor risk
Compatible Stacks
MetforminSGLT2 inhibitors (empagliflozin, dapagliflozin)Testosterone Replacement TherapyGrowth Hormone Releasing Peptides (Tesamorelin)
Join Skool to unlock full Survodutide data →